This trial is active, not recruiting.

Condition cervical cancer
Treatments radiofrequency ablation, cytokine-induced killer cells
Phase phase 2
Sponsor The First People's Hospital of Changzhou
Start date July 2015
End date June 2038
Trial size 10 participants
Trial identifier NCT02490748, cervical001


The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(No Intervention)
Patients undergo radiofrequency ablation alone.
Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
radiofrequency ablation RFA
Radiofrequency ablation is performed percutaneously under CT/US guidance
cytokine-induced killer cells CIK
The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Primary Outcomes

Recurrence-free survival
time frame: 1 year

Eligibility Criteria

Female participants from 30 years up to 70 years old.

Inclusion Criteria: - They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer. they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations—for example, women at a range of disease stages—were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer). Exclusion Criteria: - studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.

Additional Information

Official title Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
Description The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cervical cancer.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by The First People's Hospital of Changzhou.